½ÃÀ庸°í¼­
»óǰÄÚµå
1771313

¼¼°èÀÇ ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀå : ¾÷°è µ¿Çâ ¹× ¿¹Ãø - ½Å¾à °³¹ß ´Ü°èº°, ±â¾÷ ±Ô¸ðº°, Ä¡·á ¿µ¿ªº°, ÁÖ¿ä Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ±âŸ Áö¿ª)

Computer Aided Drug Discovery Market: Industry Trends and Global Forecasts - Distribution by Drug Discovery Steps, Company Size, Therapeutic Area, and Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Roots Analysis | ÆäÀÌÁö Á¤º¸: ¿µ¹® 290 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀå : °³¿ä

¼¼°èÀÇ ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀå ±Ô¸ð´Â 2,900¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ µ¿¾È 15.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ ¹× ±âȸ ºÐ¼®Àº ´ÙÀ½ ¸Å°³º¯¼ö·Î ¼¼ºÐÈ­µË´Ï´Ù.

½Å¾à °³¹ß ´Ü°èº°

  • Ÿ°Ù ½Äº°
  • Ÿ°Ù °ËÁõ
  • È÷Æ® Á¦³Ê·¹À̼Ç
  • È÷Æ® Åõ ¸®µå(HTL)
  • ¸®µå ÃÖÀûÈ­

°íºÐÀÚ À¯Çüº°

  • Ç×ü
  • ´Ü¹éÁú
  • ÆéƼµå
  • ÇÙ»ê
  • º¤ÅÍ

±â¾÷ ±Ô¸ðº°

  • ¼Ò±â¾÷
  • Áß°ß±â¾÷
  • ´ë±â¾÷

Ä¡·á ¿µ¿ªº°

  • ÀÚ°¡¸é¿ªÁúȯ
  • Ç÷¾× Áúȯ
  • ½ÉÇ÷°ü Áúȯ
  • ¼ÒÈ­±â Áúȯ
  • È£¸£¸ó Áúȯ
  • HIV/AIDS
  • °¨¿°Áõ
  • ´ë»çÁúȯ
  • Á¤½ÅÁúȯ
  • ±Ù°ñ°Ý°è Áúȯ
  • ½Å°æÁúȯ
  • Á¾¾çÇÐÀû Àå¾Ö
  • È£Èí±â Áúȯ
  • ÇǺÎÀå¾Ö
  • ºñ´¢±â°è Áúȯ
  • ±âŸ

½ºÆù¼­ À¯Çüº°

  • ¾÷°è ÁøÃâ±â¾÷
  • ºñ¾÷°è ÁøÃâ±â¾÷

ÁÖ¿ä Áö¿ª

  • ºÏ¹Ì(¹Ì±¹, ij³ª´Ù)
  • À¯·´(ÀÌÅ»¸®¾Æ, µ¶ÀÏ, ÇÁ¶û½º, ½ºÆäÀÎ, ±âŸ)
  • ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, Àεµ, ÀϺ»)

¼¼°èÀÇ ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀå : ¼ºÀå ¹× µ¿Çâ

½Ã°£ÀÌ Áö³²¿¡ µû¶ó ½Å¾à °³¹ß°ú °ü·ÃµÈ º¹À⼺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç ƯÈ÷ °íºÐÀÚ ÀǾàǰÀÇ °æ¿ì ±âÁ¸ÀÇ ÀúºÐÀÚ ÀǾàǰº¸´Ù º»ÁúÀûÀ¸·Î º¹ÀâÇÕ´Ï´Ù. ±× °á°ú, ÀǾàǰ ¼öŹ Á¦Á¶ ¹× ¹ÙÀÌ¿À Å×Å©³î·ÎÁö ºÐ¾ß¿¡¼­ ¿¬±¸ °³¹ßºñ ÀüüÀÇ Áõ°¡¸¦ º¼ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. º¹À⼺¿¡ ´õÇØ ½Å¾à °³¹ß °úÁ¤Àº ¼³ºñ ÅõÀÚ ¹× ½Ã°£ ¾ç¸é¿¡¼­ ¸Å¿ì ±î´Ù·Ó½À´Ï´Ù. ±× °á°ú ÄÄÇ»ÅÍ Áö¿ø¿¡ ÀÇÇÑ ½Å¾à °³¹ß ¼­ºñ½º°¡ ÀÌ ¹®Á¦ÀÇ ÀáÀçÀûÀÎ ÇØ°áÃ¥À¸·Î ¶°¿Ã¶ú½À´Ï´Ù.

Computer Aided Drug Discovery Market-IMG1

¼ö³â µ¿¾È ´Ù¾çÇÑ °è»ê µµ±¸¿Í ¼­ºñ½º°¡ µîÀåÇÏ¿© ÀáÀçÀû ¸®µå Èĺ¸ È­ÇÕ¹°ÀÇ ¼±ÅÃ, ¸ðµ¨¸µ, ºÐ¼® ¹× ÃÖÀûÈ­¸¦ °¡´ÉÇÏ°Ô ÇØ ¿Ô½À´Ï´Ù. ÄÄÇ»ÅÍ Áö¿ø¿¡ ÀÇÇÑ ½Å¾à °³¹ßÀÚÀÇ ¿¹Ãø·ÂÀº ¿¬±¸ÀÚ°¡ ¼ö¹é °³ÀÇ »ý¹°ÇÐÀû Ç¥Àû¿¡ °ÉÃÄ ºÐÀÚ¸¦ ¹«ÀÛÀ§·Î ½ºÅ©¸®´×ÇÏ´Â °ÍÀ» ÇÇÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© ¸Å¿ì À¯¸®ÇÏ´Ù´Â °ÍÀÌ Áõ¸íµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ÀÌ Á¢±Ù¹æ½ÄÀ» ÅëÇØ ½Å¾à °³¹ß¿¡ µå´Â ÃÑ ºñ¿ëÀÇ 35% °¡±îÀ̸¦ Àý¾àÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ±× °á°ú °íºÐÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ º¸´Ù È¿À²ÀûÀÎ ½Å¾à °³¹ß ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ´Ù´Â Á¡Àº ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù. ±× °á°ú CADD¿Í °°Àº Âü½ÅÇÑ in-silico ½Å¾à °³¹ß ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ±â¾÷Àº ÀÌÁ¦ Á¦¾à¾÷°è¿¡ ÇʼöºÒ°¡°áÇÑ Á¸Àç°¡ µÇ¾ú½À´Ï´Ù.

¼¼°èÀÇ ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀåÀÇ ÇöÀç »óŸ¦ ÆÄ°í ¾÷°è ³» ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ È®ÀÎÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä Á¶»ç °á°ú´Â ´ÙÀ½°ú °°½À´Ï´Ù.

  • 90»ç ÀÌ»óÀÇ ±â¾÷ÀÌ ´Ù¾çÇÑ À¯ÇüÀÇ »ý¹° Á¦Á¦ÀÇ ½Å¾à °³¹ß¿¡ in silico ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ Àû±ØÀûÀ¸·Î °ü¿©Çϰí ÀÖÀ¸¸ç, ÀÌ Áß ¾à 30»ç°¡ ½Å¾à °³¹ßÀÇ Àü ´Ü°è¿¡ ´ëÀÀÇÏ´Â ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌ Áß ¾à 30°³»ç°¡ ½Å¾à °³¹ßÀÇ Àü °øÁ¤À» Ä¿¹öÇÏ´Â ¼­ºñ½º¸¦ Á¦°øÇÒ ¼ö ÀÖ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ ±â¾÷Àº Ç×ü, ´Ü¹éÁú, ÆéŸÀÌµå µî ´Ù¾çÇÑ °íºÐÀÚÀÇ Á¶±â â¾à¿¡ ÃÊÁ¡À» ¸ÂÃá ±¸Á¶ ±â¹ÝÀÇ ¾à¹° µðÀÚÀÎÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • in silico ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ´ë±â¾÷ÀÇ ´ëÇ¥ÀûÀÎ ¿¹·Î´Â ChemPartner, Evotec, Jubilant Biosys, Schrodinger, Signature Discovery, WuXi AppTec µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.
  • 30% ÀÌ»óÀÇ ¼­ºñ½º Á¦°ø¾÷ü°¡ ½Å¾à °³¹ßÀÇ ¸ðµç ´Ü°è¿¡ ´ëÇØ in silico ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ´ëÁ¶ÀûÀ¸·Î, Ÿ°Ù ±â¹ÝÀÇ ½Å¾à ´Ü°è¿¡¼­´Â ±¤¹üÀ§ÇÑ ½ÇÇèÀû Áö¿øÀÌ ÇÊ¿äÇÕ´Ï´Ù.
  • ÁÖ¸ñÇØ¾ß ÇÒ °ÍÀº silico ¼­ºñ½ºÀÇ 60% °¡±îÀ̰¡, ¸ðµç À¯ÇüÀÇ Ç×ü Áß¿¡¼­µµ ´ÜÀÏŬ·ÐÇ×ü¸¦ ´ë»óÀ¸·Î Çϰí ÀÖ´Â °ÍÀÔ´Ï´Ù. À̰Ϳ¡ °è¼ÓµÇ´Â °ÍÀÌ, ´Ù¾çÇÑ À¯ÇüÀÇ ´Ü¹éÁúÀ̳ª ÆéƼµå¸¦ ´ë»óÀ¸·Î ÇÑ in silico ½Å¾à °³¹ß ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ±â¾÷ÀÔ´Ï´Ù.
  • Áß¼Ò±â¾÷ÀÇ Á¸À縦 Ư¡À¸·Î ÇÏ´Â in-silico ¼­ºñ½º Á¦°ø¾÷ü´Â ´Ù¾çÇÑ Áö¿ª¿¡ ºÐ»êµÇ¾î ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ÁøÃâ±â¾÷Àº °í°´ÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ ´Ù¾çÇÑ ºñÁî´Ï½º ¸ðµ¨À» ä¿ëÇϰí ÀÖ½À´Ï´Ù.
Computer Aided Drug Discovery Market-IMG2
  • ÀÌ ºÐ¾ß¿¡ Á¾»çÇÏ´Â ÀϺΠ±â¾÷Àº °¢°¢ÀÇ silico ±â¹Ý ¼­ºñ½º Æ÷Æ®Æú¸®¿À¸¦ °­È­Çϰí ÀÌ ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ ²ÙÁØÈ÷ ´É·ÂÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.
  • ÀΰøÁö´É ¹× Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû°ú °°Àº »õ·Î¿î ÄÄÇ»ÆÃ ±â¼ú°ú in silico Á¢±Ù¹ýÀÇ ÅëÇÕÀº ½Å¾à °³¹ß ÇÁ·Î¼¼½º Àü¹Ý¿¡ Çõ¸íÀ» °¡Á®¿Ã °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
  • ¼­ºñ½º Á¦°ø¾÷ü´Â ÀǾàǰÀÇ Å¸ÀÓ¶óÀÎÀ» °¡¼ÓÈ­Çϰí Á¦Ç°ÀÇ ¼º°øÀ» Çâ»ó½ÃŰ¸é¼­ »ó´çÇÑ ºñ¿ë Àý°¨ÀÇ ÀÌÁ¡À» °è¼Ó Á¦°øÇϱâ À§ÇØ ´Ù¾çÇÑ ºñÁî´Ï½º Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù.
  • È¿°úÀûÀÎ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿äÀÇ ³ô¾ÆÁü°ú Æø³ÐÀº Ä¡·á ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ »ý¹° Á¦Á¦ÀÇ ½Å¾à °³¹ß Ȱµ¿ Áõ°¡¿¡ ÀÇÇØ ½ÃÀåÀº ¾ÕÀ¸·Îµµ Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.
  • Àå±âÀûÀ¸·Î´Â ´Ù¾çÇÑ Áö¿ª, ½ºÆù¼­ÀÇ À¯Çü, ¼­ºñ½º Á¦°ø¾÷üÀÇ ±â¾÷ ±Ô¸ð¿¡ °ÉÃÄ, ¿¹ÃøµÇ´Â ±âȸ´Â ÃæºÐÈ÷ ºÐ»êÇϰí ÀÖ´Â °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.
Computer Aided Drug Discovery Market-IMG3

ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀåÀÇ ÁøÃâ±â¾÷ ¿¹

  • BioDuro
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Abzena
  • BioNTech
  • Sygnature Discovery
  • ChemPartner
  • Sundia MediTech
  • Viva Biotech

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ ÄÄÇ»ÅÍ ±â¹Ý ½Å¾à °³¹ß ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ½Å¾à °³¹ß ´Ü°èº°, ±â¾÷ ±Ô¸ðº°, Ä¡·á ¿µ¿ªº° µ¿Çâ, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼­¹®

  • ÀåÀÇ °³¿ä
  • ÀǾàǰÀÇ ¹ß°ß ¹× °³¹ßÀÇ Å¸ÀÓ¶óÀÎ
  • in silico ½Å¾à °³¹ß µµ±¸ÀÇ °³¿ä
  • ½Å¾à °úÁ¤¿¡¼­ in silico µµ±¸ÀÇ ¿ëµµ
  • ½Å¾à °³¹ß¾÷¹«¿¡¼­ In Silico ÅøÀÇ ÀÌ¿ëÀÇ ÀåÁ¡
  • in silico ½Å¾à °³¹ß ¿ÀÆÛ·¹À̼ÇÀÇ ½Ç½Ã¿¡ ¼ö¹ÝÇÏ´Â °úÁ¦
  • in silico ½Å¾à °³¹ß ¾÷¹«ÀÇ ¾Æ¿ô¼Ò½Ì Áõ°¡ ¿¹Ãø
  • °á·Ð

Á¦4Àå ½ÃÀå »óȲ

  • ÀåÀÇ °³¿ä
  • °íºÐÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ In Silico ½Å¾à °³¹ß ¼­ºñ½º : ¾÷°è ÁøÃâ±â¾÷ À϶÷
  • in silico ½Å¾à °³¹ß ¼­ºñ½º : ¼ÒÇÁÆ®¿þ¾î ¹× ±â¼ú À϶÷

Á¦5Àå Áß¿äÇÑ ÀλçÀÌÆ®

Á¦6Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • ÀåÀÇ °³¿ä
  • ºÏ¹Ì¿¡ º»»ç¸¦ µÐ ÁÖ¿ä in silico ¼­ºñ½º Á¦°ø ¾÷ü
    • BioDuro
    • Creative Biostructure
    • GenScript
    • LakePharma
  • À¯·´¿¡ º»»ç¸¦ µÐ ÁÖ¿ä ±â¾÷
    • Abzena
    • BioNTech
    • Sygnature Discovery
  • ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡ º»»ç¸¦ µÐ ÁÖ¿ä ±â¾÷
    • ChemPartner
    • Sundia MediTech
    • Viva Biotech

Á¦7Àå ±â¾÷ °æÀï·Â ºÐ¼®

  • ÀåÀÇ °³¿ä
  • ÁÖ¿ä ÆÄ¶ó¹ÌÅÍ
  • Á¶»ç ¹æ¹ý
  • ±â¾÷ °æÀï·Â ºÐ¼® : ºÏ¹ÌÀÇ in silico ½Å¾à °³¹ß ¼­ºñ½º Á¦°ø¾÷ü
  • ±â¾÷ °æÀï·Â ºÐ¼® : À¯·´ÀÇ in silico ½Å¾à °³¹ß ¼­ºñ½º Á¦°ø¾÷ü
  • ±â¾÷ °æÀï·Â ºÐ¼® : ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ±âŸ Áö¿ªÀÇ in silico ½Å¾à °³¹ß ¼­ºñ½º Á¦°ø¾÷ü

Á¦8Àå ÁÖ¿ä ±âȸ ºÐ¾ß

  • ÀåÀÇ °³¿ä
  • ÁÖ¿ä ÀüÁ¦ ¹× ÆÄ¶ó¹ÌÅÍ
  • Á¶»ç ¹æ¹ý
  • Ç×ü
  • ÆéƼµå
  • ´Ü¹éÁú
  • ±âŸ ¼±Áø Ä¡·á¹ý

Á¦9Àå »õ·Î¿î ºñÁî´Ï½º ¸ðµ¨ ¹× Àü·«

  • ÀåÀÇ °³¿ä
  • ÁÖ¿ä ÀüÁ¦ ¹× Á¶»ç ¹æ¹ý
  • in silico ¼­ºñ½º Á¦°ø¾÷ü : ´ë»óÀÌ µÇ´Â °íºÐÀÚ ¼ö ¹× ½Å¾à °³¹ß ´Ü°èº° ºÐ¼®
  • °á·Ð

Á¦10Àå »ç·Ê ¿¬±¸ : ÀúºÐÀÚ ¹× °íºÐÀÚÀÇ ½Å¾à °³¹ß °úÁ¤ ºñ±³

  • ÀåÀÇ °³¿ä
  • ÀúºÐÀÚ ¹× °íºÐÀÚ ÀǾàǰ ¹× Ä¡·á¹ý
  • °íºÐÀÚÀÇ ¹ß°ß ÇÁ·Î¼¼½º¸¦ °³¼±Çϱâ À§ÇÑ Á¢±Ù

Á¦11Àå Á¶»ç ÀλçÀÌÆ®

Á¦12Àå ºñ¿ë Àý°¨ ºÐ¼®

Á¦13Àå ½ÃÀå ¿¹Ãø

  • ÀåÀÇ °³¿ä
  • ¿¹Ãø Á¶»ç ¹æ¹ý ¹× ÁÖ¿ä ÀüÁ¦Á¶°Ç
  • °íºÐÀÚ¿ë in silico ½Å¾à °³¹ß ¼­ºñ½º ½ÃÀå Àüü(-2035³â)
    • °íºÐÀÚ¿ë in silico ½Å¾à °³¹ß ¼­ºñ½º ½ÃÀå(-2035³â) : ½Å¾à °³¹ß ´Ü°èº°
    • °íºÐÀÚ¿ë in silico ½Å¾à °³¹ß ¼­ºñ½º ½ÃÀå(-2035³â) : °íºÐÀÚ À¯Çüº°
    • °íºÐÀÚ¿ë in silico ½Å¾à °³¹ß ¼­ºñ½º ½ÃÀå(-2035³â) : ±â¾÷ ±Ô¸ðº°
    • °íºÐÀÚ¿ë in silico ½Å¾à °³¹ß ¼­ºñ½º ½ÃÀå(-2035³â) : Ä¡·á ¿µ¿ªº°
    • °íºÐÀÚ¿ë in silico ½Å¾à °³¹ß ¼­ºñ½º ½ÃÀå(-2035³â) : ½ºÆù¼­ À¯Çüº°
    • °íºÐÀÚ¿ë in silico ½Å¾à °³¹ß ¼­ºñ½º ½ÃÀå(-2035³â) : ÁÖ¿ä Áö¿ªº°

Á¦14Àå ½Å¾à °³¹ß¿¡¼­ in silico Åø°ú ÇâÈÄÀÇ µ¿Çâ

  • ÀåÀÇ °³¿ä
  • ºñ¿ë°ú ½Ã°£¿¡ °üÇÑ ÀáÀçÀûÀÎ ÀÌÁ¡¿¡ ÀÇÇØ ½Å¾à °³¹ß ¾÷¹«ÀÇ ¾Æ¿ô¼Ò½ÌÀº ÇâÈÄ Áõ°¡ÇÒ Àü¸Á
  • ±â¼úÀÇ Áøº¸´Â ÇöÀçÀÇ ½Å¾à °³¹ß ÇÁ·Î¼¼½º¿¡ Çõ¸íÀ» °¡Á®¿Ã °¡´É¼º »ó½Â
  • °á·Ð

Á¦15Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦16Àå ºÎ·Ï I : Ç¥ Çü½Ä µ¥ÀÌÅÍ

Á¦17Àå ºÎ·Ï II : ±â¾÷ ¹× Á¶Á÷ ¸ñ·Ï

Á¦18Àå ºÎ·Ï III : ½Å¾à °³¹ßÀ» À§ÇÑ ºñ°è»êÀû ±â¹ý

AJY

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: OVERVIEW

As per Roots Analysis, the global computer aided drug discovery market valued at USD 29 million in anticipated to grow at a CAGR of 15.6% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Drug Discovery Steps

  • Target Identification
  • Target Validation
  • Hit Generation
  • Hit-to-Lead
  • Lead Optimization

Type of Large Molecule

  • Antibodies
  • Proteins
  • Peptides
  • Nucleic Acids
  • Vectors

Company Size

  • Small Companies
  • Mid-sized Companies
  • Large Companies

Therapeutic Area

  • Autoimmune Disorders
  • Blood Disorders
  • Cardiovascular Disorders
  • Gastrointestinal and Digestive Disorders
  • Hormonal Disorders
  • HIV / AIDS
  • Infectious Diseases
  • Metabolic Disorders
  • Mental Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Oncological Disorders
  • Respiratory Disorders
  • Skin Disorders
  • Urogenital Disorders
  • Others

Type of Sponsor

  • Industry Players
  • Non-Industry Players

Key Geographical Regions

  • North America (US and Canada)
  • Europe (Italy, Germany, France, Spain and Rest of Europe)
  • Asia-Pacific (China, India and Japan)

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: GROWTH AND TRENDS

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical contract manufacturing / biotechnology sector has been witnessed. In addition to the complexities involved, the drug discovery process is extremely demanding, both in terms of capital expenses and time. Consequently, computer-aided drug discovery services have emerged as a potential solution to the cause.

Computer Aided Drug Discovery Market - IMG1

Over the years, various computational tools and services have emerged, enabling the selection, modelling, analysis and optimization of potential lead candidates. The predictive power of computer aided drug discovery providers has proven to be extremely advantageous, allowing researchers to bypass the random screening of molecules across hundreds of biological targets. Moreover, it is worth highlighting that this approach has been estimated to save nearly 35% of the total cost involved in developing a new drug, resulting in growing demand for more efficient drug discovery services for large molecules. As a result, players offering novel in-silico drug discovery services, such as CADD, have now become an integral part of the pharmaceutical industry.

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: KEY INSIGHTS

The report delves into the current state of global computer aided drug discovery market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, around 30 players claim to have the capabilities to offer services for all steps of discovery.
  • Majority of the companies offer structure-based drug design focused on early-stage drug discovery of a range of large molecules, including antibodies, proteins and peptides.
  • Prominent examples of large companies that offer in-silico services include ChemPartner, Evotec, Jubilant Biosys, Schrodinger, Sygnature Discovery, WuXi AppTec.
  • More than 30% of the service providers offer in-silico services for all the steps of drug discovery; in contrast, target-based drug discovery steps require extensive experimental support.
  • Notably, nearly 60% of the in-silico services are offered for monoclonal antibodies among all types of antibodies; this is followed by companies offering in silico drug discovery services for different types of proteins and peptides.
  • Featuring the presence of small and mid-sized firms, the in-silico service provider landscape is well distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients.
Computer Aided Drug Discovery Market - IMG2
  • Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective in-silico-based service portfolios and maintain a competitive edge in this industry.
  • The integration of novel computational techniques, such as artificial intelligence and cloud-based platforms, with in-silico approaches, is likely to revolutionize the overall drug discovery process.
  • Service providers are adopting various business strategies in order to continue providing significant cost saving advantages, along with expediting discovery timelines and improving product success.
  • Driven by the growing demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutic areas, the market is expected to witness sustained growth in future.
  • In the long-term, the projected opportunity is anticipated to be well distributed across various geographies, type of sponsors and company sizes of service providers.
Computer Aided Drug Discovery Market - IMG3

Example Players in the Computer Aided Drug Discovery Market

  • BioDuro
  • Creative Biostructure
  • GenScript
  • LakePharma
  • Abzena
  • BioNTech
  • Sygnature Discovery
  • ChemPartner
  • Sundia MediTech
  • Viva Biotech

PRIMARY RESEARCH OVERVIEW

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews conducted with the following industry stakeholders:

  • Founder and Chief Executive Officer, Company A
  • Chief Executive Officer and Chief Technical Officer, Company B
  • Senior Vice President, Drug Discovery, Company C
  • Founder, Company D

GLOBAL COMPUTER AIDED DRUG DISCOVERY MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global computer aided drug discovery market, focusing on key market segments, including [A] drug discovery steps, [B] type of large molecule, [C] company size, [D] therapeutic area, [E] type of sponsor and [F] key geographical regions.
  • Market Landscape: A comprehensive evaluation of companies offering in silico drug discovery services for large molecules, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of business model used, [E] number of drug discovery step(s) for which the company offers services involving the use of in silico approaches, [F] type of large molecules(s) handled, [G] type of in silico approach used, [H] type of in silico service(s) offered and [I] type of clientele served.
  • Key Insights: An insightful analysis of contemporary market trends that have been depicted using four schematic representations, including [A] an analysis of the industry players engaged in this domain, distributed based on the location of their company size and respective headquarters, [B] an analysis of in silico service providers, [C] a detailed analysis, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
  • Company Profiles: In-depth profiles of companies that offer in silico drug discovery services, focusing on [A] company overview, [B] financial information (if available), [C] in silico-based service(s) portfolio and [D] recent developments and an informed future outlook.
  • Company Competitiveness Analysis: A comprehensive competitive analysis of at-home self-testing kit manufacturers, examining factors, such as strength of their respective service portfolios, taking into consideration the [A] experience of a service provider, [B] number of drug discovery services offered and [C] number of large molecules, for which the aforementioned services are offered.
  • Key Opportunity Areas: In-depth analysis of current opportunity within in-silico drug discovery services market, comparing the number of pipeline products and current market size based on [A] type of large molecule and the availability and capabilities of affiliated in silico drug discovery service providers.
  • Emerging Business Models and Strategies: A comprehensive discussion on the various business strategies that can be adopted by in-silico drug discovery service providers, based on [A] the different types of large molecules handled and [B] the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
  • Cost Saving Analysis: A detailed analysis focusing on the cost saving potential associated with the use of in-silico approaches in the drug discovery process.
  • Case Study: A detailed discussion on the key challenges associated with the [A] discovery and production of large molecules, [B] affiliated product development timelines, and [C] manufacturing protocols, with those of small molecule drugs.
  • Survey Insights: Comprehensive insights from an industry-wide survey, highlighting inputs solicited from various experts who are directly or indirectly engaged in providing in silico services for discovery of large molecule drugs.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Drug Discovery and Development Timelines
  • 3.3. Overview of In Silico Drug Discovery Tools
    • 3.3.1. Historical Evolution of the In Silico Approach
    • 3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods
    • 3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development
  • 3.4. Applications of In Silico Tools in the Drug Discovery Process
    • 3.4.1. Target Identification
      • 3.4.1.1. Chemoinformatics-based Tools
      • 3.4.1.2. Network-based Drug Discovery
      • 3.4.1.3. Computational Platforms and Interaction Repositories
    • 3.4.2. Target Validation
    • 3.4.3. Hit Generation
      • 3.4.3.1. High-Throughput Screening
      • 3.4.3.2. Fragment Based Screening
      • 3.4.3.3. Virtual Screening
    • 3.4.4. Hit-to-Lead
      • 3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
      • 3.4.4.2. Other Novel Approaches
    • 3.4.5. Lead Optimization
      • 3.4.5.1. Pharmacophore Modeling
      • 3.4.5.2. Docking
      • 3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR)
      • 3.4.5.4. Molecular Modeling
  • 3.5. Advantages of using In Silico Tools for Drug Discovery Operations
  • 3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations
  • 3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations
  • 3.8. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Company Size and Location of Headquarters
    • 4.2.5. Analysis by Type of Business Model
    • 4.2.6. Analysis by Drug Discovery Steps
    • 4.2.7. Analysis by Type of Large Molecule
      • 4.2.7.1. Analysis by Type of Antibody
      • 4.2.7.2. Analysis by Type of Protein
    • 4.2.8. Analysis by Type of In Silico Approach Used
    • 4.2.9. Analysis by Types of In Silico Services Offered
    • 4.2.10. Analysis by Type of Clientele
  • 4.3. In Silico Drug Discovery Services: List of Software / Technologies

5. KEY INSIGHTS

  • 5.1. Chapter Overview
  • 5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters
  • 5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps
  • 5.4. World Map Representation: Regional Analysis of Outsourcing Activity
  • 5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Key In Silico Service Providers Based in North America
    • 6.2.1. BioDuro
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Funding and Investment Information
      • 6.2.1.3. In Silico-based Service Portfolio
      • 6.2.1.4. Recent Developments and Future Outlook
      • 6.2.1.5. Peer Group Benchmark Comparison
    • 6.2.2. Creative Biostructure
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Funding and Investment Information
      • 6.2.2.3. In Silico-based Service Portfolio
      • 6.2.2.4. Recent Developments and Future Outlook
      • 6.2.2.5. Peer Group Benchmark Comparison
    • 6.2.3. GenScript
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Funding and Investment Information
      • 6.2.3.3. In Silico-based Service Portfolio
      • 6.2.3.4. Recent Developments and Future Outlook
      • 6.2.3.5. Peer Group Benchmark Comparison
    • 6.2.4. LakePharma
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Funding and Investment Information
      • 6.2.4.3. In Silico-based Service Portfolio
      • 6.2.4.4. Recent Developments and Future Outlook
      • 6.2.4.5. Peer Group Benchmark Comparison
  • 6.3. Leading Players Based in Europe
    • 6.3.1. Abzena
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Funding and Investment Information
      • 6.3.1.3. In Silico-based Service Portfolio
      • 6.3.1.4. Recent Developments and Future Outlook
      • 6.3.1.5. Peer Group Benchmark Comparison
    • 6.3.2. BioNTech
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Funding and Investment Information
      • 6.3.2.3. Recent Developments and Future Outlook
      • 6.3.2.4. Peer Group Benchmark Comparison
    • 6.3.3. Sygnature Discovery
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Funding and Investment Information
      • 6.3.3.3. In Silico-based Service Portfolio
      • 6.3.3.4. Recent Developments and Future Outlook
      • 6.3.3.5. Peer Group Benchmark Comparison
  • 6.4. Leading Players Based in Asia-Pacific
    • 6.4.1. ChemPartner
      • 6.4.1.1. Company Overview
      • 6.4.1.2. In Silico-based Service Portfolio
      • 6.4.1.3. Recent Developments and Future Outlook
      • 6.4.1.4. Peer Group Benchmark Comparison
    • 6.4.2. Sundia MediTech
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Funding and Investment Information
      • 6.4.2.3. In Silico-based Service Portfolio
      • 6.4.2.4. Recent Development and Future Outlook
      • 6.4.2.5. Peer Group Benchmark Comparison
    • 6.4.3. Viva Biotech
      • 6.4.3.1. Company Overview
      • 6.4.3.2. Funding and Investment Information
      • 6.4.3.3. In Silico-based Service Portfolio
      • 6.4.3.4. Recent Development and Future Outlook
      • 6.4.3.5. Peer Group Benchmark Comparison

7. COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Key Parameters
  • 7.3. Methodology
  • 7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
  • 7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
  • 7.6. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World

8. KEY OPPORTUNITY AREAS

  • 8.1. Chapter Overview
  • 8.2. Key Assumptions and Parameters
  • 8.3. Methodology
  • 8.4. Antibodies
    • 8.4.1. Developer Landscape
      • 8.4.1.1. Number of Pipeline Molecules
      • 8.4.1.2. Affiliated Market Size and Growth Rate
    • 8.4.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.5. Peptides
    • 8.5.1. Developer Landscape
      • 8.5.1.1. Number of Pipeline Molecules
      • 8.5.1.2. Affiliated Market Size and Growth Rate
    • 8.5.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.6. Proteins
    • 8.6.1. Developer Landscape
      • 8.6.1.1. Number of Pipeline Molecules
      • 8.6.1.2. Affiliated Market Size and Growth Rate
    • 8.6.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size
  • 8.7. Other Advanced Therapies
    • 8.7.1. Developer Landscape
      • 8.7.1.1. Number of Pipeline Molecules
      • 8.7.1.2. Affiliated Market Size and Growth Rate
    • 8.7.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

9. EMERGING BUSINESS MODELS AND STRATEGIES

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Methodology
  • 9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered
    • 9.3.1. Strategies for Short Term Success
    • 9.3.2. Strategies for Long Term Success
  • 9.4. Concluding Remarks

10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES

  • 10.1. Chapter Overview
  • 10.2. Small Molecule and Large Molecule Drugs / Therapies
    • 10.2.1. Comparison of Key Specifications
    • 10.2.2. Comparison of Manufacturing Processes
    • 10.2.3. Comparison of Drug Discovery Processes
  • 10.3. Approaches to Improve Discovery Process of Large Molecules

11. SURVEY INSIGHTS

  • 11.1. Chapter Overview
  • 11.2. Overview of Respondents
    • 11.2.1. Designation of Respondents
  • 11.3. Survey Insights
    • 11.3.1. Drug Discovery Steps
    • 11.3.2. Type of Molecules Handled
    • 11.3.3. In Silico Drug Design Focused Service Portfolio
    • 11.3.4. Likely Adoption of In Silico Tools for Large Molecules Drug Discovery
    • 11.3.5. Current Market Opportunity
    • 11.3.6. Likely Growth Rate
    • 11.3.7. Cost Saving Potential of the In Silico Approach

12. COST SAVING ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions
  • 12.3. Methodology
  • 12.4. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, Till 2035
  • 12.5. Concluding Remarks

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall In Silico Drug Discovery Services Market for Large Molecules, Till 2035
    • 13.3.1. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, Till 2035
      • 13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, Till 2035
      • 13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, Till 2035
      • 13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, Till 2035
      • 13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, Till 2035
      • 13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, Till 2035
    • 13.3.2. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, Till 2035
      • 13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, Till 2035
      • 13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, Till 2035
      • 13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, Till 2035
      • 13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, Till 2035
      • 13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, Till 2035
    • 13.3.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, Till 2035
      • 13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, Till 2035
      • 13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies, Till 2035
      • 13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, Till 2035
    • 13.3.4. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, Till 2035
      • 13.3.4.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, Till 2035
      • 13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, Till 2035
      • 13.3.4.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, Till 2035
      • 13.3.4.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and Digestive Disorders, Till 2035
      • 13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, Till 2035
      • 13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS), Till 2035
      • 13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, Till 2035
      • 13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of Metabolic Disorders, Till 2035
      • 13.3.4.9. In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, Till 2035
      • 13.3.4.10. In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, Till 2035
      • 13.3.4.11. In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, Till 2035
      • 13.3.4.12. In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders Till 2035
      • 13.3.4.13. In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, Till 2035
      • 13.3.4.14. In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, Till 2035
      • 13.3.4.15. In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, Till 2035
      • 13.3.4.16. In Silico Drug Discovery Services Market for Large Molecules: Share of Others, Till 2035
    • 13.3.5. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, Till 2035
      • 13.3.5.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, Till 2035
      • 13.3.5.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, Till 2035
    • 13.3.6. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, Till 2035
      • 13.3.6.1. In Silico Drug Discovery Services Market for Large Molecules: Share of North America, Till 2035
        • 13.3.6.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of US, Till 2035
        • 13.3.6.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, Till 2035
      • 13.3.6.2. In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, Till 2035
        • 13.3.6.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, Till 2035
        • 13.3.6.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share in France, Till 2035
        • 13.3.6.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, Till 2035
        • 13.3.6.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, Till 2035
        • 13.3.6.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, Till 2035
        • 13.3.6.2.6. In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, Till 2035
      • 13.3.6.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, Till 2035
        • 13.3.6.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share in China, Till 2035
        • 13.3.6.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share in India, Till 2035
        • 13.3.6.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, Till 2035

14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY

  • 14.1. Chapter Overview
  • 14.2. Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
  • 14.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
    • 14.3.1. Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve Overall Efficiency and Productivity
    • 14.3.2. Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process
    • 14.3.3. Rising Interest in Use of Force Fields for In Silico Drug Discovery
  • 14.4. Concluding Remarks

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Company A
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Founder and Chief Executive Officer
  • 15.3. Company B
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Chief Executive Officer and Chief Technical Officer
  • 15.4. Company C
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: Senior Vice President, Drug Discovery
  • 15.5. Company D
    • 15.5.1. Company Snapshot
    • 15.5.2. Interview Transcript: Founder

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

18. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦